在私立医疗保健机构接受治疗的非小细胞肺癌患者的生存及预后因素

Survival and prognostic factors in patients with non-small cell lung cancer treated in private health care.

作者信息

Araujo Luiz Henrique de Lima, Baldotto Clarissa Seródio, Zukin Mauro, Vieira Fernando Meton de Alencar Camara, Victorino Ana Paula, Rocha Viviani Ribeiro, Helal Rafaela Cordeiro, Salem Jonas Hauben, Teich Nelson, Ferreira Carlos Gil

机构信息

COI Institute for Education and Research, Rio de Janeiro, RJ, Brazil.

出版信息

Rev Bras Epidemiol. 2014 Dec;17(4):1001-14. doi: 10.1590/1809-4503201400040017.

DOI:10.1590/1809-4503201400040017

PMID:25388498

Abstract

INTRODUCTION

Outcomes data on Non-Small Cell Lung Cancer (NSCLC) are scarce with regard to the private health care in Brazil. The aim of this study was to describe the characteristics, treatments performed, and the survival of patients with NSCLC in a Brazilian private oncologic institution.

METHODS

Medical charts from patients treated between 1998 and 2010 were reviewed, and data were transferred to a clinical research form. Long-term follow-up and survival estimates were enabled through active surveillance.

RESULTS

Five hundred sixty-six patients were included, and median age was 65 years. Most patients were diagnosed in advanced stages (79.6% III/IV). The overall survival was 19.0 months (95%CI 16.2 - 21.8). The median survival was 99.7, 32.5, 20.2, and 13.3 months for stages I, II, III, and IV, respectively (p < 0.0001). Among patients receiving palliative chemotherapy, the median survival was 12.2 months (95%CI 10.0 - 14.4).

CONCLUSIONS

The outcomes described are favorably similar to the current literature from developed countries. Besides the better access to health care in the private insurance scenario, most patients are still diagnosed in late stages.

摘要

引言

关于巴西私立医疗保健中非小细胞肺癌（NSCLC）的结局数据稀缺。本研究的目的是描述巴西一家私立肿瘤机构中NSCLC患者的特征、所接受的治疗以及生存情况。

方法

回顾了1998年至2010年间接受治疗患者的病历，并将数据转移至临床研究表格。通过主动监测实现长期随访和生存估计。

结果

纳入了566例患者，中位年龄为65岁。大多数患者在晚期被诊断（79.6%为III/IV期）。总生存期为19.0个月（95%CI 16.2 - 21.8）。I、II、III和IV期的中位生存期分别为99.7、32.5、20.2和13.3个月（p < 0.0001）。在接受姑息化疗的患者中，中位生存期为12.2个月（95%CI 10.0 - 14.4）。